MAB858-2
Anti-RSV Antibody, glycoprotein, all type A, B strains, clone 131-2G
clone 131-2G, from mouse
Synonim(y):
RSV
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Polecane produkty
pochodzenie biologiczne
mouse
Poziom jakości
forma przeciwciała
purified immunoglobulin
rodzaj przeciwciała
primary antibodies
klon
131-2G, monoclonal
reaktywność gatunkowa
human
producent / nazwa handlowa
Chemicon®
metody
ELISA: suitable
immunofluorescence: suitable
izotyp
IgG1κ
Warunki transportu
wet ice
Opis ogólny
RSV is a labile paramyxovirus that produces a characteristic fusion of human cells in tissue culture--the syncytial effect. Two subtypes, A and B, have been identified. Subtype B are characterized as the asymptomatic strains of the virus. The more severe clinical illnesses involve Subtype A strains.
Specyficzność
Glycoprotein, 89 kD. Recognizes both A and B strains.
Immunogen
A2
Epitope: some type B strains
Zastosowanie
Detect Respiratory Syncytial Virus using this Anti-RSV Antibody, glycoprotein, all type A, B strains, clone 131-2G validated for use in ELISA & IF.
ELISA
Indirect Immunofluorescence (fresh frozen tissue sections)
Final working dilutions must be determined by end user.
Indirect Immunofluorescence (fresh frozen tissue sections)
Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
Postać fizyczna
Format: Purified
Purified immunoglobulin. 1 mg/mL in 0.02M PB with 0.25M NaCl, pH=7.6 containing 0.1% sodium azide.
Przechowywanie i stabilność
Maintain at 2 to 8° C in aliquots for up to 12 months after date of receipt. Do not store in diluted format.
Inne uwagi
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Informacje prawne
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Oświadczenie o zrzeczeniu się odpowiedzialności
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Ta strona może zawierać tekst przetłumaczony maszynowo.
Nie możesz znaleźć właściwego produktu?
Wypróbuj nasz Narzędzie selektora produktów.
Kod klasy składowania
10 - Combustible liquids
Klasa zagrożenia wodnego (WGK)
WGK 2
Temperatura zapłonu (°C)
Not applicable
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Virology journal, 7, 114-114 (2010-06-08)
Respiratory syncytial virus (RSV) is a primary cause of serious lower respiratory tract illness for which there is still no safe and effective vaccine available. Using reverse genetics, recombinant (r)RSV and an rRSV lacking the G gene (DeltaG) were constructed
Exploratory Spatial Analysis of in vitro Respiratory Syncytial Virus Co-infections.
Viruses null
Journal of virology, 93(7) (2019-01-18)
Human respiratory syncytial virus (RSV) is a major pediatric respiratory pathogen. The attachment (G) and fusion (F) glycoproteins are major neutralization and protective antigens. RSV G is expressed as membrane-anchored (mG) and -secreted (sG) forms, both containing a central fractalkine-like
NPJ vaccines, 7(1), 168-168 (2022-12-20)
Respiratory syncytial virus (RSV) infection in children is the most common viral respiratory infection and can cause severe lung damage or death. There is no licensed vaccine for preventing RSV infection. Previously we demonstrated that an RSV vaccine, BARS13, consisting
Journal of virology, 96(7), e0220121-e0220121 (2022-03-11)
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease of children, the elderly, and immunocompromised individuals. Currently, there are no FDA-approved RSV vaccines. The RSV G glycoprotein is used for viral attachment to host cells
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej